FDA Gives Fast Track Designation for Emergent BioSolutions' (EBS) NuThrax
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) announces the FDA has granted Fast Track Designation for the company's investigational anthrax vaccine, NuThrax(TM).
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JPMorgan Reinstates Emergent BioSolutions (EBS) at Underweight
- AstraZeneca's Tagrisso and Orpathys combo meets Phase III goals
- FDA grants accelerated approval to Ultragenyx gene therapy for GSDIa
Create E-mail Alert Related Categories
FDA, Hot FDA NewsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
